

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**REGENERON PHARMACEUTICALS, INC.,**  
*Petitioner*

v.

**NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,**  
*Patent Owners.*

---

**Case: IPR2021-00816**  
Patent No. 9,220,631

---

**PATENT OWNERS REQUEST FOR ORAL ARGUMENT  
PURSUANT TO 37 C.F.R. § 42.70(a)**

Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corp. (together “Patent Owners” or “Novartis”) respectfully requests oral argument pursuant to 37 C.F.R. § 42.70(a); the Board’s Scheduling Order (Paper 14); and the Board’s email correspondence dated June 10, 2022. Novartis has conferred with Petitioner Regeneron Pharmaceuticals, Inc. (“Petitioner”), and the parties agreed to request that the hearing, scheduled for July 21, 2022, at 11:30 AM ET, be conducted in person at USPTO Headquarters in Alexandria, Virginia.

Novartis also respectfully requests that an option be made available for in-house counsel to attend the hearing virtually, either by video or telephone. Petitioner does not object to this request.

Pursuant to 37 C.F.R. § 42.70(a) and without waiving any issue not specifically identified herein, Novartis hereby submits this Request for Oral Argument on issues related to the patentability of the challenged claims of U.S. Patent No. 9,220,631. Novartis intends to discuss the issues raised in the parties’ filings under the ongoing review, including but not limited to, the following:

1. Any issues properly raised by Petitioner, including the Petition and Petitioner’s Reply, and any exhibits relied on therein;
2. Any issues raised by the Board’s Institution Decision dated October 26,

2021 (Paper 13); and

3. Any issues addressed in Novartis's papers, including in Novartis's Response and Novartis's Sur-Reply, and any exhibits relied on therein.

Novartis requests the ability to reserve a portion of its total time for presenting sur-rebuttal arguments after Petitioner's rebuttal. See November 2019 Consolidated Trial Practice Guide at 83.

If oral argument will be held in-person at a hearing room in the USPTO Office, Novartis requests the ability to use a computer, projector, and screen to display possible demonstrative exhibits. Novartis also requests that the attorneys at Novartis's counsel table be allowed to use computers.

Dated: June 14, 2022

Respectfully submitted,

/Elizabeth Holland/

Elizabeth J. Holland (Reg. No. 47,657)

Allen & Overy LLP

1221 Avenue of the Americas

New York, NY 10020

Tel: 212-610-6375

[elizabeth.holland@allenovery.com](mailto:elizabeth.holland@allenovery.com)

*Counsel for Patent Owners Novartis  
Pharma AG, Novartis Technology  
LLC, and Novartis Pharmaceuticals  
Corporation*

## **CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. 42.70(a), the undersigned hereby certifies that on June 14, 2022 a copy of the foregoing **PATENT OWNER'S REQUEST FOR ORAL ARGUMENT** was served via electronic mail, as agreed to by counsel, upon the following counsel for Petitioner:

Elizabeth S. Weiswasser (Reg. No. 55,721)  
Anish R. Desai (Reg. No. 73,760)  
Natalie Kennedy (Reg. No. 68,511)  
Andrew Gesior (Reg. No. 76,588)  
WEIL GOTSHAL & MANGES LLP  
767 Fifth Avenue  
New York, NY 10153

Brian E. Ferguson (Reg. No. 36,801)  
Christopher Pepe (Reg. No. 73,851)  
Priyata Y. Patel (Reg. No. 76,861)  
WEIL, GOTSHAL & MANGES LLP  
2001 M Street, N.W., Suite 600  
Washington, DC 20036

Petra Scamborova  
Petra.scamborova@regeneron.com  
James T. Evans  
James.evans@regeneron.com (Reg. No. 64,377)  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, NY 10591

Email: [Regeneron.IPR.Service@weil.com](mailto:Regeneron.IPR.Service@weil.com)

Dated: June 14, 2022

Respectfully submitted,

/Frank ReDavid/

Frank ReDavid  
Litigation Specialist  
Allen & Overy LLP